<DOC>
	<DOCNO>NCT00605722</DOCNO>
	<brief_summary>This single arm study evaluate efficacy safety combination Tarceva Avastin patient advance metastatic liver cancer . Patients treat Tarceva 150 mg po daily plus Avastin 5 mg/kg intravenous ( iv ) every 2 week . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Avastin ( Bevacizumab ) Patients With Advanced Metastatic Liver Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>adult patient , ≥ 18 year age ; advanced metastatic liver cancer ; ≥ 1 measurable lesion , previously treat local therapy within 4 week enrollment . prior concomitant systemic anticancer treatment advanced disease ; patient high risk variceal bleeding ; clinically significant cardiovascular disease ; major surgery , open biopsy , significant traumatic injury within 4 week study start .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>